Division of Teva Pharmaceutical Industries Ltd.
Latest From Immuneering Corp.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.
Immuneering Corp. is developing mathematical models to predict whether a drug is likely to activate a patient's immune system to aid in fighting cancer and autoimmune diseases. The company's modeling application works with data from patient blood and tumor samples. Immuneering plans to offer its services to drug makers as a way of sorting patients into subpopulations, to understand the workarounds cancers develop against therapies, and to predict efficacy.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Benjamin Zeskin, PhD, CEO
Kevin D Fowler, PhD, VP, Translational Research
Scott Barrett, MD, CMO
- Contact Info
Phone: (617) 500-8080
P.O. Box 426057 Cambridge, MA 02142-0019